Their waist size, blood pressure, A1c, and cholesterol all got worse with the regain
GLP-1 receptor agonists, by achieving greater weight loss than obtained with other medications, may represent a therapeutic opportunity for improving obesity in patients with PsO and HS, with resulting decrease in CVR and, in general, improvement in the medium to long term
As there is no meaningful expression of GLP-1 receptors on hepatocytes, the major effect of GLP-1 agonists on MASH is likely to be indirect and may be related to a reduction in calorie intake, body weight and insulin resistance, all of which would lead to reduced liver lipid accumulation and hepatic inflammation 7,8
Atherosclerosis 220 , 381386 (2012)
a process that highlights the efficiency of the mechanisms of cellular specification (Merkle et al., 2004